Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1

Trial Profile

Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMLSG23-14/Palbo Basket Study
  • Most Recent Events

    • 06 Dec 2016 Interim results (n=6) of phase Ib part of the study assessing safety and tolerability, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jul 2015 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018 as per ClinicalTrials.gov record.
    • 15 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top